Nasal, oral antiseptics show antiviral activity against SARS-CoV-2

By The Science Advisory Board staff writers

May 15, 2020 -- Veloce BioPharma has reported that its nasal and oral antiseptics are effective against SARS-CoV-2, the virus responsible for COVID-19.

Researchers at the Institute for Antiviral Research at Utah State University tested the company's Halodine nasal and oral antiseptic preparations against the novel coronavirus. They found the solutions were effective against SARS-CoV-2 even when diluted far below available commercial strength, according to Veloce BioPharma.

The Halodine solutions contain a proprietary povidone-iodine antiseptic formulation for repeated nasal and oral use. It is the first iodine-based antiseptic to be active against the novel coronavirus, the lead author noted in a press release.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?